Should You Get Gardasil 9 After Completing Gardasil 4 as a Teenager?
No, you should not routinely receive Gardasil 9 if you completed the Gardasil 4 series as a teenager—the additional cancer prevention benefit is minimal and the cost-effectiveness is poor, making it a lower priority than other HPV vaccination strategies.
The Evidence Against Revaccination
The key issue is that Gardasil 4 already protects against HPV types 16 and 18, which cause approximately 70% of all HPV-related cancers 1. Gardasil 9 adds five additional high-risk types (31,33,45,52, and 58) that account for only an additional 14% of HPV-related cancers in women and 4% in males 1.
Cost-effectiveness modeling demonstrates that revaccinating previously Gardasil 4-vaccinated individuals with Gardasil 9 costs over $100,000 per quality-adjusted life-year gained 2. Two independent models—a simplified dynamic HPV model and the complex US HPV-ADVISE model—both concluded that the incremental cost per QALY was $146,200 and $108,200 respectively when assuming no cross-protection from Gardasil 4 2. Even in sensitivity analyses, the cost per QALY ranged from $70,300 to $182,000 2.
This strategy is far less efficient than simply increasing primary Gardasil 9 vaccine coverage in unvaccinated populations 2.
Why Gardasil 4 Provides Substantial Protection
Your completed Gardasil 4 series provides:
- Protection against HPV 6 and 11, which cause 90% of genital warts 1
- Protection against HPV 16 and 18, responsible for the vast majority of cervical, anal, penile, vaginal, vulvar, and oropharyngeal cancers 1
- Long-term immunity that has demonstrated sustained effectiveness in post-marketing surveillance 1
Clinical Context and Timing Considerations
The greatest benefit from HPV vaccination occurs when administered before any HPV exposure, which typically happens soon after sexual debut 3. Since you were vaccinated as a teenager, you likely received protection before exposure to the most oncogenic HPV types 1.
Approximately 40% of college women and 60% of college men acquire HPV within the first two years after first sexual intercourse 1, 3. Your early vaccination with Gardasil 4 positioned you to prevent infection with the most dangerous HPV types during this high-risk period 1, 3.
What About the Additional Five Types in Gardasil 9?
While Gardasil 9 does offer broader protection, the incremental benefit for someone already vaccinated with Gardasil 4 is limited 2. The five additional types (31,33,45,52,58) contribute to a minority of HPV-related cancers, and you may have already been exposed to some of these types if you are sexually active 4, 2.
HPV vaccines do not protect against types to which you have already been exposed at the time of vaccination 3, 5. This means that revaccination with Gardasil 9 would only benefit you for the additional five types to which you have not yet been exposed 4, 3.
Current Guidelines Do Not Support Revaccination
No major guideline organization (ACIP, AAP, American Cancer Society) recommends revaccinating individuals who completed a Gardasil 4 series with Gardasil 9 1, 6, 7, 3. The focus of current recommendations is on:
- Ensuring catch-up vaccination for those not adequately vaccinated through age 26 7, 3
- Increasing primary vaccine coverage in adolescents 6, 3
- Initiating vaccination earlier (ages 9-12) to maximize completion rates 6, 3
Important Caveats
Continue routine cervical cancer screening regardless of vaccination status 3. HPV vaccination does not replace screening, as vaccines do not treat existing infections or protect against all oncogenic HPV types 3.
If you are over age 26 and considering any HPV vaccination, the benefit is substantially reduced 6, 7. The American Cancer Society specifically states that providers should inform individuals aged 22-26 who were not previously vaccinated that vaccination at older ages is less effective in lowering cancer risk 6. For adults aged 27-45, ACIP recommends shared clinical decision-making only for those at risk for new HPV exposure, recognizing minimal benefit 7, 3.
Bottom Line
Your completed Gardasil 4 series provides robust protection against the HPV types responsible for the majority of HPV-related cancers and genital warts 1. Revaccination with Gardasil 9 is not cost-effective and is not recommended by any major guideline organization 6, 7, 3, 2. Focus instead on maintaining routine cancer screening and ensuring that unvaccinated individuals in your community receive primary HPV vaccination 6, 3, 2.